Page 190 of 286 · 8,574 total

patent

Abbott Laboratories et al. v.MIRACOR MEDICAL SA

· IPR2025-00116

Abbott Laboratories has filed an IPR petition seeking cancellation of 18 claims of Miracor’s LVAD patent (US 11,754,077). The petition alleges obviousness over four prior‑art references and argues the petition is not barred. The Board’s decision on institution is pending.

patent

Innoscience America, Inc. et al. v.Infineon Technologies Americas Corp.

· IPR2025-00175

Innoscience seeks to invalidate all 17 claims of Infineon’s 8,686,562 patent covering III‑V semiconductor electrical contacts, arguing they are anticipated or obvious over four prior‑art references.

patent

Aardevo North America, LLC et al. v.Agventure B.V.

· IPR2025-00136

Aardevo North America challenges Agventure's 2021 potato hybrid seed patent, asserting that all ten claims are anticipated or obvious based on decades of prior art. The petition lists nine grounds covering anticipation and obviousness over publications dating back to 1971. No secondary considerations are offered.

patent

Micron Technology, Inc. et al. v.Yangtze Memory Technologies Company, Ltd.

· IPR2025-00118

Micron has filed an IPR petition challenging all 14 claims of Yangtze Memory’s ESD bus patent, arguing obviousness over Yoshinaga, Saint, and Haralabidis and asserting no discretionary denial grounds.

patent

Kubota North America Corporation et al. v.Vermeer Manufacturing Company

· IPR2025-00170

Kubota has filed an IPR petition challenging all 36 claims of Vermeer’s ’750 patent covering compact tool carriers. The challenger relies on Korean patent KR996, and U.S. patents Bares and Beltrami to argue obviousness under §103. The petition also argues that discretionary denial is inappropriate.

patent

Ericsson, Inc. v.Motorola Mobility LLC

· IPR2025-00174

Ericsson has filed an IPR petition seeking cancellation of Motorola’s 5G DMRS patent (U.S. 11,184,130). The petition alleges anticipation and obviousness based on 3GPP standards documents TR 38.912 and two R1 technical reports.

patent

Apple Inc. v.DH International Ltd

· IPR2025-00172

Apple has filed an IPR petition seeking to invalidate claims 1‑20 of DH International’s ’294 patent, arguing the claims are obvious over Suga and Gorsuch. The petition requests institution and argues no discretionary denial grounds exist.

patent

Abbott Laboratories et al. v.MIRACOR MEDICAL SA

· IPR2025-00113

Abbott Laboratories has filed an IPR petition seeking cancellation of Miracor’s LVAD patent (U.S. 11,376,415). The petition argues that the claims are obvious in view of four prior‑art references covering magnetically driven rotary pumps.

patent

Samsung Electronics Co., Ltd. et al. v.SiOnyx, LLC

· IPR2025-00162

Samsung has filed an IPR petition to cancel 79 claims of SiOnyx’s 10,224,359 image‑sensor patent, asserting that the claims are anticipated or obvious over Iida and other prior art. The petition also argues that a discretionary denial would be improper.

patent

BabyBjorn AB et al. v.The Ergo Baby Carrier, Inc. et al.

· IPR2025-00111

BabyBjörn has filed an IPR petition challenging The Ergo Baby Carrier’s adjustable child‑carrier patent, asserting anticipation and obviousness over multiple prior‑art references and arguing indefiniteness of a key claim term.

patent

Abbott Laboratories et al. v.MIRACOR MEDICAL SA

· IPR2025-00114

Abbott Laboratories has filed an IPR petition challenging Miracor Medical’s U.S. Patent 11,572,879 covering an implantable LVAD. The petition asserts that four prior‑art references render all asserted claims obvious under 35 U.S.C. §103. The case is currently pending before the PTAB.

patent

Jumio Corporation v.FaceTec, Inc.

· IPR2025-00109

Jumio Corporation has filed an IPR petition seeking to invalidate FaceTec's facial‑authentication patent (U.S. 11,874,910) on obviousness grounds, citing multiple prior‑art references. The petition also argues that discretionary denial under §314(a) and §325(d) is improper.

patent

Abbott Laboratories et al. v.MIRACOR MEDICAL SA

· IPR2025-00115

Abbott Laboratories has filed an IPR petition challenging Miracor Medical’s 11,674,517 LVAD patent, asserting that all 19 challenged claims are obvious over four prior‑art references. The petition argues that the prior art discloses every claim limitation and that discretionary denial is unwarranted.

patent

ResMed Corp. v.Cleveland Medical Devices, Inc.

· IPR2025-00157

ResMed has filed a petition for inter partes review of Cleveland Medical Devices' ’284 patent covering a networked PAP therapy system, arguing that the claims are obvious over prior PAP and telemedicine technologies.

patent

BabyBjorn AB et al. v.The Ergo Baby Carrier, Inc. et al.

· IPR2025-00110

BabyBjörn has filed an IPR petition challenging The Ergo Baby Carrier’s 2023 adjustable child carrier patent, asserting that all 24 claims are anticipated or obvious over existing baby‑carrier manuals and patents.

patent

Abbott Laboratories et al. v.MIRACOR MEDICAL SA

· IPR2025-00112

Abbott Laboratories has filed an IPR petition seeking cancellation of Miracor Medical’s 357 Patent covering a magnetically levitated LVAD. The petition relies on four prior‑art references to argue that all challenged claims are obvious under 35 U.S.C. §103.

patent

Jumio Corporation v.FaceTec, Inc.

· IPR2025-00108

Jumio Corporation petitions the PTAB to invalidate FaceTec’s facial‑authentication patent, arguing that its claimed camera‑optics technique is obvious over prior art such as Derakhshani, Tanii, Zhang, Tahk, and Suzuki. The petition seeks institution of an IPR on claims 1‑24.

patent

LifeScan, Inc. et al. v.Cellspin Soft, Inc.

· IPR2025-00102

LifeScan, Senseonics and Ascensia have filed a petition to review CellSpin Soft’s U.S. Patent 11,234,121 covering a Bluetooth‑enabled data capture device. They assert the claims are obvious over multiple prior‑art references and lack written‑description support, seeking institution of the IPR.

patent

Jumio Corporation v.FaceTec, Inc.

· IPR2025-00107

Jumio Corporation petitions the PTAB to invalidate FaceTec’s facial‑authentication patent, arguing that all 20 claims are obvious over prior art such as Derakhshani, Tanii, Zhang and Tahk, and that discretionary denial is improper.

patent

Jumio Corporation v.FaceTec, Inc.

· IPR2025-00106

Jumio has filed an IPR petition seeking cancellation of all 20 claims of FaceTec’s facial‑authentication patent, arguing obviousness over multiple prior‑art references and opposing discretionary denial.

patent

LifeScan, Inc. et al. v.Cellspin Soft, Inc.

· IPR2025-00104

LifeScan, Senseonics and Ascensia have filed a petition to institute an IPR against Cellspin Soft’s 8,904,030 patent, asserting that the claims are obvious over several Bluetooth‑related prior arts and lack priority. The petition also cites discretionary factors favoring institution.

patent

LifeScan, Inc. et al. v.Cellspin Soft, Inc.

· IPR2025-00103

LifeScan and co‑petitioners seek IPR of Cellspin Soft’s 9,900,766 patent, asserting that claims 1‑15 are obvious over multiple prior‑art references and lack valid priority. They also highlight discretionary factors favoring institution.

patent

Imperative Care, Inc. v.Inari Medical, Inc.

· IPR2025-00156

Imperative Care seeks an IPR on Inari Medical’s 11,697,012 catheter‑hemostasis valve patent, asserting anticipation and obviousness over Schaffer and related references. The petition argues the preamble term “aspiration” is non‑limiting and requests the Board to institute the review.

patent

Abbott Laboratories et al. v.MIRACOR MEDICAL SA

· IPR2025-00096

Abbott Laboratories has filed an IPR petition seeking cancellation of claims 1‑7, 10, and 12‑13 of Miracor’s U.S. Patent 11,351,356 covering a catheter‑based LVAD. The petition argues that four prior‑art references disclose every claim limitation, making the claims obvious under §103. The Board has not yet ruled on institution or denial.

patent

Innoscience America, Inc. et al. v.Infineon Technologies Americas Corp.

· IPR2025-00094

Innoscience has filed an IPR petition seeking cancellation of all 16 claims of Infineon’s 8,264,003 GaN cascode patent, arguing that each claim is obvious over known prior‑art combinations. The petition also argues that discretionary denial is improper.

patent

MediaTek Inc. v.DAEDALUS PRIME LLC

· IPR2025-00100

MediaTek has filed an IPR petition challenging all 24 claims of Daedalus Prime’s ’838 patent covering a hardware security engine for secure communications. The petition argues obviousness based on prior art combinations and seeks institution of the review.

patent

American Axle & Manufacturing, Inc. et al. v.Neapco Components, LLC

· IPR2025-00090

American Axle seeks IPR on Neapco’s 11,434,958 patent covering a joint‑assembly with an access window. The petition argues the claims are anticipated by the 2016 Jeep Renegade service manual and obvious over that manual combined with Krude ʼ422 and Sugiyama. No secondary considerations are shown, and the petitioner urges the Board to institute the IPR.

patent

Nuvei Technologies, Inc. et al. v.Autoscribe Corporation

· IPR2025-00089

Nuvei Technologies has filed an IPR petition seeking cancellation of all 27 claims of Autoscribe’s ’621 patent covering online payment tokenization. The challenger asserts the claims are obvious over prior art references Stringfellow, Kloster, and Carlson.

patent

Samsung Electronics Co., Ltd. et al. v.Netlist, Inc.

· IPR2025-00002

Samsung has filed an IPR petition seeking to invalidate Netlist’s 11,880,319 patent covering memory‑module signaling. The petition relies on obviousness over Hazelzet combined with JEDEC, Buchmann, Wang, and Kim references, and cites prior IPR estoppel. The Board has yet to rule.

patent

American Axle & Manufacturing, Inc. et al. v.Neapco Components, LLC

· IPR2025-00091

American Axle has filed an IPR petition challenging Neapco’s 11,598,376 drivetrain joint‑assembly patent, asserting that the claims are anticipated by a 2016 Jeep Renegade service manual and obvious in view of that manual combined with Krude ’422 and Sugiyama.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →